Skyhawk Therapeutics Appoints Aaron Deves as Chief Commercial Officer to Lead Commercialization of SKY-0515 for Huntington's Disease [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
BOSTON March 10, 2026 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies to modulate critical RNA targets for a series of challenging neurological diseases, announces the appointment of Aaron Deves as Chief Commercial Officer. Mr. Deves brings more than 30 years of experience commercializing therapies for neurological disorders, including for chorea associated with Huntington's disease (HD) with AUSTEDO ® . SKY-0515 is Skyhawk's lead program and is being developed as a potential disease-modifying therapy for Huntington's disease. Aaron Deves, Skyhawk Chief Commercial Officer "Skyhawk may receive accelerated approval for SKY-0515 in Australia within the next twelve months, and in other major markets during 2027," said Bill Haney, CEO of Skyhawk Therapeutics. "Aaron's 30 years of experience successfully building commercial teams and launching innovative drugs for challenging neurological conditions helps prep
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Yahoo Finance [Yahoo! Finance]Yahoo! Finance
- Is It Too Late To Reassess Teva Pharmaceutical Industries (TEVA) After Its 75% One Year Rally? [Yahoo! Finance]Yahoo! Finance
- Is Teva Pharmaceutical Industries (TEVA) A Good Stock To Buy Now? [Yahoo! Finance]Yahoo! Finance
- Does Blackstone's Private Credit Strains And AI Push With Anthropic Reshape The Bull Case For BX? [Yahoo! Finance]Yahoo! Finance
- A Look At Teva Pharmaceutical Industries (TEVA) Valuation After Recent Share Price Pullback [Yahoo! Finance]Yahoo! Finance
TEVA
Earnings
- 1/28/26 - Beat
TEVA
Sec Filings
- 3/17/26 - Form 144
- 3/9/26 - Form 4
- 3/9/26 - Form 4
- TEVA's page on the SEC website